Boehringer Ingelheim, MD Anderson partner on pancreatic cancer
Boehringer Ingelheim, based in Germany, and The University of Texas MD Anderson Cancer Center have joined forces in a collaborative effort focused on developing innovative medicines for pancreatic ductal adenocarcinoma (PDAC).
The new collaboration combines MD Anderson’s unique understanding of potential drivers of PDAC with Boehringer Ingelheim’s experience in drug discovery and development.
Pancreatic cancer accounts for 4% of cancer deaths worldwide (330,000 people) and is the seventh-most common cause of death from cancer. Pancreatic cancer is anticipated to become the second-leading cause of cancer-related death in the U.S. before 2030. Newly diagnosed patients have a median survival of less than one year, and a five-year survival rate of only 3% to 5%. PDAC is one of the most lethal cancers due to its late detection and resistance to available standard-of-care therapy. Effective medicines directed against PDAC are therefore urgently needed.
The collaboration will focus on identifying and developing therapeutic concepts in novel target areas as well as identification of biomarkers that can accurately identify patients who would respond to potential new therapies.
“At MD Anderson, we have created integrated platforms that will enable the discovery of more effective therapeutics for cancer patients,” said Timothy Heffernan, executive director and co-leader for MD Anderson’s Center for Co-Clinical Trials. “This alliance combines expertise in cancer genetics and translational medicine with outstanding drug discovery and development and it has great potential to conquer devastating diseases like pancreatic cancer.”